Eli Lilly And Company ((LLY)), Rigel Pharmaceuticals ((RIGL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of LY3871801 in treating adults with active moderate-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.
The study is testing LY3871801, an orally administered drug, against a placebo. The intervention involves different dosages of LY3871801 to assess its effectiveness and safety in comparison to the placebo group.
This randomized, double-blind study uses a parallel assignment model, ensuring that neither participants nor investigators know who receives the drug or placebo. The primary goal is treatment-focused, aiming to provide a new therapeutic option for rheumatoid arthritis.
The study began on April 28, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 22, 2025. These dates are crucial as they indicate the study’s progress and anticipated milestones.
The outcome of this study could significantly impact Eli Lilly and Rigel Pharmaceuticals’ stock performance and investor sentiment, especially if LY3871801 proves effective. Success could position these companies favorably against competitors in the rheumatoid arthritis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.